105105-00-8

Basic information

• Product Name: 4-(2,3-DIHYDRO-INDOL-1-YL)-4-OXO-BUTYRIC ACID
• Synonyms: TIMTEC-BB SBB000588;BUTTPARK 22\07-40;4-(2,3-DIHYDRO-INDOL-1-YL)-4-OXO-BUTYRIC ACID;AKOS BB/0055;1-(3-CARBOXYPROPIONYL) INDOLINE;4-(indolin-1-yl)-4-oxobutanoic acid
• CAS NO: 105105-00-8
• Molecular Formula: C₁₂H₁₃NO₃
• Molecular Weight: 219.24
• Mol File: 105105-00-8.mol

Chemical Properties

• Boiling Point: 503.2±43.0 °C(Predicted)
• Appearance: /
• Density: 1.301±0.06 g/cm3(Predicted)
• PKA: 4.53±0.17(Predicted)
• CAS DataBase Reference: 4-(2,3-DIHYDRO-INDOL-1-YL)-4-OXO-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2,3-DIHYDRO-INDOL-1-YL)-4-OXO-BUTYRIC ACID(105105-00-8)
• EPA Substance Registry System: 4-(2,3-DIHYDRO-INDOL-1-YL)-4-OXO-BUTYRIC ACID(105105-00-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 105105-00-8(Hazardous Substances Data)

Usage

Uses

Used in Biological Studies:
4-(2,3-Dihydro-1H-indol-1-yl)-4-oxobutanoic Acid is used as a screening agent for identifying and studying LsrK kinase inhibitors. This application is crucial in the development of new therapeutic agents targeting specific kinases, which are key regulatory enzymes in various cellular processes.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-(2,3-Dihydro-1H-indol-1-yl)-4-oxobutanoic Acid serves as a lead compound for the design and synthesis of novel inhibitors targeting LsrK kinase. 4-(2,3-DIHYDRO-INDOL-1-YL)-4-OXO-BUTYRIC ACID's structure provides a foundation for medicinal chemists to modify and optimize its properties to enhance its efficacy and selectivity as a kinase inhibitor.
Used in Drug Discovery:
4-(2,3-Dihydro-1H-indol-1-yl)-4-oxobutanoic Acid is utilized in drug discovery processes to explore its potential as a therapeutic agent. Its unique structure may offer new avenues for treating diseases where LsrK kinase plays a significant role, such as certain types of cancer or inflammatory conditions.
Overall, 4-(2,3-Dihydro-1H-indol-1-yl)-4-oxobutanoic Acid is a valuable compound in the realm of biological research and pharmaceutical development, with its primary applications centered around the identification and development of LsrK kinase inhibitors.

Upstream product

• 496-15-1 1-indoline 
• 314284-83-8 methyl 4-(indolin-1-yl)-4-oxobutanoate 
• 108-30-5 succinic acid anhydride 

Downstream Products

• 73356-94-2 azepinoindole-4,7-dione 
• 314284-83-8 methyl 4-(indolin-1-yl)-4-oxobutanoate 

Relevant articles and documents

Convenient synthesis of 7-hydroxyindole

7-Hydroxyindole, the key building block for the synthesis of AJ-9677 1, was prepared from indoline in six steps in 36% overall yield. AJ-9677 1 is a potent and selective adrenaline β3-agonist being considered as a clinical candidate to treat obesity in those who are suffering from diabetes.

Structural Insights into Notum Covalent Inhibition

The carboxylesterase Notum hydrolyzes a palmitoleate moiety from Wingless/Integrated(Wnt) ligands and deactivates Wnt signaling. Notum inhibitors can restore Wnt signaling which may be of therapeutic benefit for pathologies such as osteoporosis and Alzhei

Lactam derivative as well as preparation method and medical application thereof

The invention relates to lactam derivatives, and a preparation method and medical application thereof. Specifically, the invention relates to lactam derivatives as shown in a general formula (I), a preparation method of the lactam derivatives, pharmaceuti

INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD

The subject invention concerns methods and compounds for inhibiting Shp2. In one embodiment, a compound of the invention has a chemical structure as shown in formula I or II: wherein X, Y, and Z are independently N or S; R1 is cycloalkyl, heter

Design, synthesis, and discovery of 5-piperazinyl-1,2,6,7-tetrahydro-5H-azepino[3,2,1-hi]indol-4-one derivatives: A novel series of mixed dopamine D2/D4 receptor antagonist

5-Piperazinyl-1,2,6,7-tetrahydro-5H-azepino[3,2,1-hi]indol-4-one derivatives were designed, synthesized, and identified as a new series of mixed dopamine D2/D4 receptor antagonists. This series featured a rigid tricyclic ring system

Rational Design of an Indolebutanoic Acid Derivative as a Novel Aldose Reductase Inhibitor Based on Docking and 3D QSAR Studies of Phenethylamine Derivatives

A series of 45 phenethylamine derivatives were synthesized and evaluated for their inhibitory activity against pig kidney aldose reductase (ALR2, EC 1.1.1.21). Their IC50 values ranged from 400 μM to 24 μM. The binding modes of compounds at the active site of ALR2 were examined using flexible docking. The results indicated that phenethylamine derivatives nicely fit into the active pocket of ALR2 by forming various hydrogen bonding and hydrophobic interactions. 3D-QSAR analysis was also conducted using FlexX-docked alignment of the compounds. The best prediction was obtained by CoMSIA combined with hydrophobic and hydrogen bond donor/acceptor field (q 2 = 0.557, r2 = 0.934). A new derivative, 4-oxo-4-(4-hydroxyindole)butanoic acid, was designed, taking into account the CoMSIA field and the binding mode derived by FlexX docking. This rationally designed compound exhibits an ALR2 inhibition with an IC50 value of 7.4 μM, which compares favorably to that of a well-known ALR2 inhibitor, tolrestat (IC50 = 16 μM) and represents a potency approximately 240-fold higher than that of an original phenethylamine lead compound, YUA001.